Matisse Capital’s Solid Biosciences SLDB Stock Holding History

Matisse Capital’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,033	Closed	-$37K	–	160
2021 Q3	$37K	Hold	1,033	–	–	0.01%	147
2021 Q2	$57K	Sell	1,033 -134	-11%	-$8.85K	0.02%	147
2021 Q1	$96K	Buy	1,167 +134	+13%	+$14.8K	0.03%	159
2020 Q4	$117K	Sell	1,033 -600	-37%	-$37.9K	0.04%	148
2020 Q3	$50K	Hold	1,633	–	–	0.02%	144
2020 Q2	$72K	Sell	1,633 -1,667	-51%	-$69.2K	0.02%	154
2020 Q1	$118K	Sell	3,300 -227	-6%	-$11.2K	0.05%	174
2019 Q4	$235K	Sell	3,527 -1,066	-23%	-$118K	0.17%	93
2019 Q3	$712K	Buy	4,593 +193	+4%	+$21.8K	0.87%	32
2019 Q2	$380K	Buy	4,400 +20	+0.5%	+$2.18K	0.48%	51
2019 Q1	$604K	Buy	+4,380	New	+$1.1M	0.73%	35
2018 Q4	–	Sell	-540	Closed	-$382K	–	115
2018 Q3	$382K	Buy	+540	New	+$339K	0.34%	71

Other funds holding SLDB

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Matisse Capital's SLDB Position: Q4 2021 in Review

Matisse Capital sold out of Solid Biosciences (SLDB) in Q4 2021, closing a stake of 1,033 shares — an estimated $37K sold.

Matisse Capital first reported a position in SLDB in Q3 2018 and held it in 12 quarters. The position peaked at $712K in Q3 2019. 82 funds tracked by Wall St. Rank hold SLDB as of Q4 2021.

Matisse Capital reported no remaining Solid Biosciences position as of Q4 2021 after selling out during the quarter.
Matisse Capital sold 1,033 Solid Biosciences shares in Q4 2021, an estimated $37K.
Matisse Capital first reported a position in Solid Biosciences in Q3 2018 and held it in 12 quarters.
Matisse Capital's Solid Biosciences position peaked at $712K in Q3 2019.
82 funds tracked by Wall St. Rank held Solid Biosciences as of Q4 2021.

Based on Matisse Capital's 13F filing for Q4 2021, filed 4 Feb 2022.